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and SG outcomes from members of the general public who were asked to evaluate
hypothetical health states. Two researchers, with a third acting as adjudicator,
independently undertook the review of the literature, the inclusion/exclusion pro-
cess and data extraction. Statistical analyses were performed on study arms (stud-
ies) for differences and/or correlation between utility scores derived from TTO and
SG. RESULTS: Of the 170 publications yielded by the initial literature search, 19
pertinent articles were included in the present analysis, covering 24 disease cate-
gories, 77 studies and 17,515 subjects. The overall weighted mean health utility
scores were 0.82 with TTO and 0.83 with SG. Studies reporting a greater than 10%
absolute difference between the two measurement tools represented 13% (k10),
while 22% reported greater than 10% relative difference (k17), 51% reported over-
all higher utility scores with SG (k39) and 13% reported equal scores (k10). The
most common disease category, discussed in 8 studies covering 2,490 participants,
was ocular disease. Spearman’s rank test yielded significant positive correlation (r
 0.924). CONCLUSIONS: The majority of studies displayed little difference in
scores between the TTO and SG methods collected from the general public. A high
positive correlation was observed between utility scores reported by the two meth-
ods.
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OBJECTIVES: As the patient perspective becomes increasingly critical in this era of
patient-centric care and patient cost-sharing, a better understanding of research
methodologies and their impact on validity of responses is required to assess the
growing body of patient research. Increasingly, researchers are able to leverage
technology in order to access patient panels; however, questions remain as to their
robustness and representativeness. Here, we review the underlying survey re-
sponse differences obtained from both nonprobability and probability-based pa-
tient samples accessed via online survey panels and the potential impact to pa-
tient-centered research. METHODS: A review was conducted of a mixed-method
patient survey examining self-identified smokers and motivation to quit, which
utilized both probability and nonprobability samples. Survey results were com-
pared from 1,427 probability and 5,425 nonprobability patient samples. The prob-
ability sample was obtained from a statistically valid online panel, representative
of the US population. Survey responses between groups were compared using
Student’s t-test and Chi-square tests. RESULTS: The probability sample reported
smoking more cigarettes per day (p0.001) and were more likely to report smoking
every day (p0.001). Additionally, patients in the nonprobability sample were more
likely to report that they planned to quit smoking in the next 30 days (p0.001) and
that they had made an attempt to quit smoking in the past 6 months (p0.001).
CONCLUSIONS: Survey results for patient reported outcomes studies obtained
through nonprobability sampling varied significantly from those obtained through
probability sampling; and response variation is unpredictable. Calibrating non-
probability samples with probability samples using specific screening questions
may minimize bias in the resulting estimates in the larger combined sample. In
order for patient-centered outcomes research to play a meaningful role in health
care policy and decision making, rigorous probability sampling methodologies
must be applied in order to allow interpretation of results with high confidence.
PRM108
RELIABILITY, VALIDITY, AND ABILITY TO DETECT CHANGE OF THE FACT-AN
FOR USE IN PATIENTS WITH ANAEMIA ASSOCIATED WITH CHRONIC KIDNEY
DISEASE
Wiklund I1, Jin Y2, Chen WH2, van Nooten F3, Garcia-Hernandez A4, Holmstrom S4
1United BioSource Corporation, London, UK, 2United BioSource Corporation, Bethesda, MD, USA,
3Astellas Pharma Europe B.V., Leiderdorp, The Netherlands, 4Astellas Pharma Global
Development, Leiderdorp, The Netherlands
OBJECTIVES: This study assessed the measurement properties of the Functional
Assessment of Cancer Therapy – Anaemia (FACT-An) for use in patients with anae-
mia associated with chronic kidney disease (CKD). METHODS: FACT-An data were
collected in an open label dose titration, randomised phase 2b clinical trial (study
FGCL-4592-041) with non-dialysis CKD patients with anaemic stages 3 and 4.
FACT-An was completed at baseline, and treatment Weeks 9 and 17. RESULTS:
Data from 145 patients were analyzed. Average age was 64.4 yrs (SD11.3), 63%
were female. Average hemoglobin (Hb) level was 9.7 g/dL (SD0.7), 11.4 (SD1.2),
and 11.7 (SD1.1) at baseline, Weeks 9 and 17, respectively. Internal consistency
and test-retest reliability were 0.70 for all subscales, except the Emotional Well-
being subscale (EWB). Convergent validity was shown by correlations between
FACT-An Total score, Anaemia subscale, and Fatigue subscale with SF-36v2 Phys-
ical Functioning (0.57-0.61) and Vitality (0.73-0.76). Correlations were low between
FACT-An Total score, Anaemia subscale, and Fatigue subscale and Hb level at
baseline (0.14-0.15), but increased at treatment Weeks 9 (0.16-0.20) and 17 (0.23-
0.26). A responder analysis showed that FACT-An Anaemia and Fatigue subscales
were responsive in detecting small but significant changes in Hb level at week 9.
The FACT-An Total score, Anaemia subscale, and Fatigue subscale, were able to
detect SF-36v2 Vitality score increase of 5 points from baseline to Week 17. Based
on distributional and anchor-based methods, the minimally important difference
was estimated as score change of 8-10 for FACT-An Total score, 4-7 for Anaemia
subscale, and 3-5 for Fatigue subscale. CONCLUSIONS: This study shows the
FACT-An Total score, Anaemia subscale, and Fatigue subscale to be a reliable, valid,
and responsive instrument for CKD patients with anaemia. Results on the ability to
detect Hb changes were limited due to the narrow range of Hb values available in
this study.
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OBJECTIVES: To test the face and content validity of the US-English version of draft
patient satisfaction questionnaires for subcutaneous (SC) (referred to as the ‘RASQ-
SC’) and intravenous (IV) (referred to as the ‘RASQ-IV’) administrations of treat-
ment for Non-Hodgkin’s Lymphoma (NHL).METHODS:Qualitative interviews were
conducted with 10 US-English speaking adults from 2 US cities who had received an
IV administered NHL treatment in the past 4 weeks. The interviews began with a
concept elicitation (CE) section which focused on eliciting information relating to
the patients’ IV treatment experiences and perceptions of satisfaction and impacts
of a SC administration. Patients were then shown a short video showing the SC
administration process. The draft satisfaction questionnaires were then cogni-
tively debriefed (CD) using a “think-aloud” exercise to explore the content validity
of the RASQ-SC and the RASQ-IV. Interview transcripts were thematically analysed
using Atlas.ti software employing a grounded theory approach. RESULTS: Patients
were aged 43-77 years and 70% were female. Seventy percent of patients were
diagnosed with diffuse large B-cell lymphoma and 30% with indolent B-cell, stages
ranging from 1-4. Qualitative analysis demonstrated that the RASQ-IV and
RASQ-SC have excellent coverage of the treatment satisfaction and impact con-
cepts reported by patients in the CE section and during the debriefing of the RASQ-
IV. Patients’ demonstrated a good understanding of all item wording, instructions,
response scales and the recall period in the RASQ-SC. A small number of minor
revisions were made to further improve patient understanding and aid consistent
interpretation. CONCLUSIONS: The findings indicate that overall the RASQ-SC and
RASQ-IV had strong face and content validity and, following some minor revisions,
will measure the key differentiators that are important and relevant for the differ-
ent NHL treatment administration options. The instruments are appropriate for
inclusion in trials as secondary or exploratory endpoints.
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OBJECTIVES: The FDA’s Guidance for Industry, on Patient-Reported Outcome (PRO)
Measures: Use in Medical Product Development and to Support Labeling Claims
noted that validation of PRO in adults does not provide evidence for pediatrics[1].
PRO development and validation in pediatrics involves different processes, as out-
lined in a forthcoming ISPOR Good Research Practices report (GRPr)[2]. The research
objective was to consider recently implemented qualitative research strategies in
pediatrics aged 12-17 years with an orphan disease to inform the best practices for
PRO development in this population. METHODS: Consistent with the GRPr for PRO
research in pediatrics, focus groups (FGs) and individual interviews (IDIs) were
planned in Germany, Switzerland, Turkey, the UK and the United States (US). Dis-
cussions with local physicians preceded recruitment, which served as an opportu-
nity for them to relay parents’ concerns and reveal variances among adolescents
with an orphan disease. Informed consent and EC approval were obtained. A 2 x 2
(gender: female, male x age cohort: 12-14, 15-17) design of focus groups accommo-
dated social differences. RESULTS: Adolescent recruitment is complex, especially
in an orphan disease sample. Identifying eligible adolescents with an orphan dis-
ease who may remain asymptomatic until later in life was challenging, and parents
were not always willing to provide consent. Consequently, we conducted more IDIs
and fewer FGs than planned. Although US-based ethics review was a standard
process, European ECs had no formal process for concept elicitation and all issued
tacit or explicit waivers. CONCLUSIONS:Qualitative research for PRO development
in adolescents with an orphan disease requires a unique approach. We recom-
mend a 3-4 month lead time from protocol finalization to meeting commencement.
When designing protocol and recruitment strategies, researchers should ensure
adequate pediatric protections and seek EC approval. ECs should develop review
processes specifically for future PRO development research.
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Patient-reported outcome (PRO) assessment for pediatric populations is complex.
Potential variations in cognitive development and disease impact/treatment
across a wide age range present challenges for PRO assessment. Epidermolysis
bullosa (EB) is a rare, incurable genetic skin disorder primarily affecting children.
Common clinical manifestations are skin blistering and chronic wounds. Children
with EB and their families face numerous health-related quality of life (HRQOL)
issues. OBJECTIVES: To identify and evaluate HRQOL measures for use with chil-
dren (aged 3 years) with EB. METHODS: A structured PubMed search was con-
ducted using Medical Subject Heading search terms. Of the 143 abstracts identified,
40 were appropriate for further evaluation; 33 articles underwent full-text review.
Content validity and other psychometric properties of identified HRQOL measures
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were evaluated based on US and European PRO/HRQOL guidance criteria.RESULTS:
The review identified 8 HRQOL measures used with EB patients: 3 generic (SF-36;
EQ-5D, EQ-5DY); 4 dermatology-specific (DLQI, CDLQI, DQOLS, Skindex); and 1 EB-
specific (QOLEB). Only the CDLQI and QOLEB were specifically designed for pediat-
ric populations (ages 4-16 and 10 years, respectively). The QOLEB was the only
instrument for which content was derived from EB patients; 26 patient interviews
were conducted, of which 9 were with patients 18 years. Despite pediatric input
during development, not all QOLEB content is relevant to children/adolescents;
items assessing family and financial impact are not appropriate for these respon-
dents. Psychometric properties have been established among pediatric EB patients
only for the QOLEB (convergent validity [DLQI: R  0.774]; internal consistency [
0.931]; test-retest reliability [R  0.843]). CONCLUSIONS: Few published measures
meet current regulatory standards for HRQOL evaluation in pediatric EB patients.
Given the age range for EB, an HRQOL instrument that evaluates age-appropriate
concepts was not identified. Further research is needed to document and assess
HRQOL concepts in pediatric patients with EB.
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OBJECTIVES:To compare the rate and cost of traditional versus on line recruitment
methods to medical surveys in 2 different patient populations. METHODS: We
compared traditional to on line advertising in 2 separate projects (conducted in the
UK) across the same time period using the same internet and social media recruit-
ment methodologies allowing a comparison of the costs and effectiveness. By look-
ing at 2 quite distinct populations – the first being cholesterol lowering agents, thus
an older age with cardiovascular disease and the second women with problem
periods, hence a younger and otherwise healthy group we could evaluate the re-
cruitment methods. RESULTS: All costs are direct payments and exclude labour;
Cholesterol lowering agents; Traditional methods – recruitment through chain of
pharmacists using leaflets; 303 patients recruited over 9 months; cost/ survey £3.94.
Internet/Social media – adverts placed on facebook.com, google and third party ad
network; 3812 visitors to website; cost/ visitor £0.23; 572 survey completions over 11
weeks; cost/ survey £1.53. Problem Periods: Traditional methods – magazine ad-
verts, exhibition stand, press releases; 232 Women recruited over 8 weeks; Cost/
survey £18; Internet/Social Media; 6000 visitors to website over 11 weeks; cost/
visitor £0.30; 1534 survey completions over 11 weeks; cost/ survey £1.51.
CONCLUSIONS: Whilst traditional methods of recruiting participants were suc-
cessful, they were generally slower and cost more per person recruited. Internet
advertising and use of social media sites offers the potential of rapid, cost effective
recruitment. This result however does not tell us if the traditional adverts were
making it more likely people would search on line, thus driving the on line recruit-
ment or if the statins population (our statin population mean age was 62) is repre-
sentative of older age groups where it is anticipated that more traditional adver-
tising would be required.
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OBJECTIVES: The MFSAF Diary is a refined version of the Myeloproliferative Neo-
plasm Symptom Assessment Form (MPN-SAF) designed to measure the impact of
MF-related symptoms. Six symptoms are rated on a scale from 0 (absent) to 10
(worst imaginable): 1) night sweats; 2) itching (pruritus); (3) abdominal discomfort;
4) filling up quickly when you eat (early satiety); 5) pain under ribs on left side; and
6) bone or muscle pain. The objective of this study is to present the development of
a generic Spanish version to be used in Mexico, Spain, and the USA. METHODS: 1)
Concept definition; 2) Development of a Spanish translation in Mexico, Spain, and
the USA; 3) Creation of a reconciled Spanish version using the three Spanish ver-
sions as a basis; 4) Backward translation of the reconciled version; 5) Cognitive
interviews with five patients in each country. RESULTS: The development of the
reconciled version did not show major difficulties. For instance, “bone or muscle
pain” was translated as “dolor en los huesos o músculos,” and well understood by
patients. It was agreed that the use of nouns (huesos/musculos for bones/muscles)
was more appropriate as people with a very low education level might have diffi-
culties to understand adjectives such as “óseo” (osseous). Patients had difficulties
with “itching (pruritus)” translated at first by “comezón/prurito/picor.” It was im-
possible to find a common term for the three countries, and a compromise was
found with the use of the association of “comezón/picor,” with “comezón” widely
used in Mexico and “picor” in Spain. “Prurito” could not be chosen for all countries
since it was problematic for Spanish patients. CONCLUSIONS: The creation of a
generic Spanish version of the MFSAF Diary was made possible by developing
Spanish versions in Mexico, Spain, and the USA, and accepting compromises when
common terms could not be used.
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OBJECTIVES: The Repeatable Battery for the Assessment of Neuropsychological
Status (RBANS) was initially developed as a neuropsychological screening tool for
dementia. It is now commonly used to screen for abnormal cognitive decline across
a range of clinical populations. The Picture Naming subtest, a confrontation-nam-
ing task requiring subjects to name 10 line drawings, is used to assess basic verbal
functions and language skills. This abstract presents the challenges faced during
the translation of 40 pictured words into 13 languages (Bulgarian, Chinese for Tai-
wan, Czech, English and French for Canada, German, Hindi, Hungarian, Kannada,
Korean, Marathi, and Spanish for Mexico and the USA).METHODS: In each country,
a thorough forward translation was performed including two translators and a
speech therapist, all native speakers of the target languages. Criteria for selecting
substitute items were developed in instances where literal translations would be
culturally inappropriate (i.e., substitutes should match the frequency of use of the
source terms, belong to the same semantic field, be familiar to all people and easily
drawn). Finally, a clinician’s review was performed. RESULTS: Eleven of the 40
source words had to be substituted. The languages that required the most substi-
tutions were Bulgarian, Chinese, Hindi, Hungarian, Kannada, Korean, and Marathi,
whereas few substitutions were needed for languages culturally close to US English
(Canadian English and French, German, and US Spanish). The most culturally prob-
lematic picture words were “Barn” and “Toboggan/Sled.” “Barn”, for example, was
replaced by the word “House” and its corresponding picture in eight out of the 13
languages. CONCLUSIONS: This project demonstrates that translating pictured
words meaningfully in a clinical research context requires the collaboration of the
developer to correctly interpret the original, translators for their knowledge of
language, a speech therapist for his/her understanding of the word’s function, and
a clinician to validate the chosen word’s relevance.
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OBJECTIVES: Multiple sclerosis (MS) is the most common disabling neurological
disease of young adults and is associated with significant economic and Health-
Related Quality-of-Life burden. Cost-effectiveness models in MS are commonly
structured on health states reflecting progressing disease severity, represented by
scores on the Expanded Disability Status Scale (EDSS) 0-9, whereby single utility
and cost values are applied to each EDSS state in the model. Using EQ5D-5L results
from an Irish outpatient cohort of 212 patients with MS, the aim of this study was
to model the relationship between utility and EDSS. METHODS: The association
between disease severity and quality of life in MS was determined using a piece-
wise linear regression where EDSS scores were treated as discrete indicator vari-
ables. The model was fitted in WinBUGs; with the constraint that increasing EDSS
score is associated with a disimprovement in quality of life. The mapping between
utility and EDSS can be determined from these data. RESULTS: Disease severity
(EDSS) had a significant negative impact on HRQoL (p0.001). A non-linear decline
in utility was observed with the most dramatic declines occurring once patients
reach EDSS 6 and beyond. Mean utility values from the piecewise linear regression
ranged from 0.88 (EDSS 0) to 0.22 (EDSS 9), and were associated with smaller
standard errors than a simple linear model. The greatest utility decrease was be-
tween EDSS 6 and 7 (0.15) and EDSS 7 and 8 (0.41). CONCLUSIONS: The decline
in HRQoL in MS is multifactorial, but can be explained primarily by the severity of
the disease. The application of one linear model to the data was not justified. The
piecewise regression improved model efficiency and reduced sampling variability
by utilising the trends in utility decline between EDSS states.
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OBJECTIVES: To explore how patients and payers perceive value and risk and
investigate the role of patient-reported outcomes.METHODS:Quintiles surveyed a
variety of US and UK stakeholders including: an online survey of payers (US man-
aged care, UK National Health Service) and a telephone survey of adult patients
being treated for a chronic disease.RESULTS:Between January and March 2012, 144
payers (75 US, 72 UK National) and 1009 patients (509 US and 500 UK) were sur-
veyed. In general, payers were more optimistic that the quality of health care
would be improved 10 years from now than patients (68% US / 66% UK payers vs.
49% US / 38% UK patients). From the payer perspective, over 80% of payers support
use of risk sharing for: 1) population-based performance guarantees (i.e., coverage
dependent on meeting a benefit target) and 2) Coverage with Evidence Develop-
ment (CED) deals (i.e., future review based on real-world product evidence). High
administration costs (66%), difficulties in agreeing on definition of success (67%),
and difficulties in accurately measuring treatment success (63%) are among main
problems. With 77% of US and 73% UK payers supporting the shift to a more pa-
tient-oriented approach to treatment assessment, it is not surprising that PROs are
the metric most commonly used to assess risk/benefit (60% and 71% respectively).
Patients are in agreement with payers that PROs are most important in how they
evaluate the value of medicines (51% US, 60% UK). Other important drivers of
patient value: helping people live longer (14% US, 24% UK) and affordability (25%
US, 2% UK). CONCLUSIONS: Payers and patients agree that use of PRO data is
critical to assessing value and benefit-risk for prescription medicines. The shift to
A481V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 2 7 7 – A 5 7 5
